10-Q: Moderna Q1 2026 Financial Results and Litigation Update

Moderna reports a $1.34 billion net loss for Q1 2026, driven by a $950 million litigation settlement with Arbutus and Genevant.

Summary

• Total revenue for Q1 2026 was $389 million, up from $108 million in Q1 2025, primarily due to increased international COVID vaccine sales.
• Net loss for the quarter was $1.34 billion, or $3.40 per share, compared to a $971 million loss in the prior-year period.
• Operating expenses rose to $1.78 billion, largely due to an $878 million charge related to the Arbutus/Genevant litigation settlement.
• Cash, cash equivalents, and investments totaled $7.46 billion as of March 31, 2026.
• The company maintains a $1.5 billion credit facility, with $600 million drawn as of the end of the quarter.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-cautious report; while the resolution of major litigation is a long-term positive, the immediate financial impact is severe and highlights the ongoing challenges of transitioning to a sustainable commercial business model.

Positives

• Net product sales grew 309% year-over-year to $352 million.
• Successful resolution of worldwide patent litigation with Arbutus and Genevant provides long-term certainty for the infectious disease portfolio.
• Marketing authorization received from the European Commission for mCOMBRIAX (mRNA-1083) in April 2026.
• Strategic collaboration established with Recordati for the development and commercialization of mRNA-3927.
• Research and development expenses decreased by 24% year-over-year, reflecting disciplined cost management.

Negatives

• Significant net loss of $1.34 billion for the quarter.
• Cost of sales increased 961% to $955 million, heavily impacted by the one-time litigation settlement charge.
• Inventory write-downs of $38 million recorded during the quarter.
• Interest income declined 20% due to lower average investment balances and interest rates.

Risks

• Potential for an additional $1.3 billion payment depending on the outcome of the appeal regarding the 1498 Disputed Matter.
• Ongoing patent litigation with Pfizer, BioNTech, GSK, and others.
• Uncertainty regarding future demand for COVID and RSV vaccines as the market becomes more competitive.
• Reliance on successful clinical trial outcomes for the oncology and rare disease pipeline.
• Exposure to variable interest rates on the $600 million outstanding term loan.

Future Outlook

The company expects a return to sales growth in 2026, supported by long-term government partnerships. It anticipates cost of sales to remain consistent with 2025 levels (excluding settlement impacts) and expects a modest reduction in R&D expenses due to portfolio prioritization.

Management Comments

• Management emphasizes the importance of the Arbutus/Genevant settlement in providing certainty for the infectious disease portfolio.
• The company remains committed to advancing its pipeline, including intismeran autogene and norovirus programs.
• Management expects to maintain sufficient liquidity to fund operations through at least the next 12 months.

Industry Context

StockSavvy.ai notes that Moderna is transitioning from a pandemic-era high-growth phase to a more competitive, commercial-stage biotech model. The resolution of major patent litigation is a critical step in de-risking the company's long-term intellectual property strategy, though the financial burden remains significant.

Comparison to Industry Standards

• Moderna's R&D spend remains high relative to smaller biotech peers, consistent with its strategy to maintain a broad clinical pipeline.
• The company's reliance on COVID-19 vaccine revenue is being mitigated by the launch of mRESVIA and the approval of mCOMBRIAX, aligning with industry trends toward diversified respiratory portfolios.
• The $950 million settlement is a substantial one-time charge, but it removes a significant legal overhang that has weighed on the company's valuation compared to competitors like Pfizer and BioNTech.

Legal Proceedings

• Settlement reached with Arbutus and Genevant on March 3, 2026.
• Ongoing patent litigation with Pfizer, BioNTech, GSK, Northwestern University, and others.
• Shareholder class action and derivative litigation related to mRNA-1345 (RSV vaccine).

Stakeholder Impact

• Shareholders face dilution and earnings pressure due to the significant net loss and potential for further litigation-related payments.
• Creditors are protected by the company's strong cash position and compliance with credit facility covenants.
• Customers and healthcare providers benefit from the expansion of the respiratory vaccine portfolio.

Next Steps

• Payment of $950 million settlement to Arbutus/Genevant in Q3 2026.
• Potential data readout for mRNA-3927 in 2026.
• Potential approval of mRNA-1010 seasonal flu vaccine in 2026.
• Phase 3 adjuvant melanoma data readout expected in 2026.

Key Dates

Recommendation

The stock is a hold as the company navigates a transition period. While the litigation settlement removes a major uncertainty, the financial results show significant pressure, and the company's future growth depends heavily on the successful commercialization of its new respiratory vaccines and the progress of its oncology pipeline.

Keywords

Moderna, mRNA, Biotechnology, Vaccines, Spikevax, mRESVIA, mCOMBRIAX, Patent Litigation, Financial Results